About WuXi AppTec DMPK
As a global DMPK service provider, we are committed to delivering all clients with high-quality data, precise R&D strategies, and excellent services to meet the unique needs of clients and become the preferred partner for DMPK studies.
WuXi AppTec DMPK Briefly
WuXi AppTec DMPK leverages over 18 years of experience and a track record of over 1,500 successful IND filings. Operating in the United States (New Jersey) and China (Shanghai, Suzhou, Nanjing, and Nantong), it specializes in pharmacokinetics studies. When you partner with WuXi AppTec for drug discovery and development services, you gain access to an integrated worldwide network of facilities that offer a full range of discovery screening, preclinical development, and clinical drug metabolism and pharmacokinetics (DMPK) platforms and services. These include in vitro absorption, distribution, metabolism, excretion (ADME) studies, in vivo pharmacokinetic studies, metabolite profiling and identification studies, radiolabeled compound synthesis, radiolabeled in vivo ADME studies, and Non-GLP bioanalysis.
18+
Years of experience
1,000+
Employees
1,600+
Global clients
1,500+
Successful IND filings supported
200+
Assay types
300k+
In vitro studies each year
20k+
In vitro studies each year
180k+
Samples analyzed per week
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
Why Choose WuXi AppTec DMPK ?
-
Fast and Reliable Data Delivery
No lead time for in vitro and in vivo assays
Fast turnaround time
Meet IND and NDA requirements of FDA, NMPA, and EMA
Successfully pass over 15 years of audits
-
High-Throughput Automation Platforms
Fully automated in vitro ADME workstation
Fully automated bioanalysis sample pretreatment system
Automatic blood sampling and plasma separation system
-
Experienced and Professional Teams
Dedicated study director provides specialized project management
Professional teams dedicated to experimental design, implementation, and report delivery
-
High Standard Instruments and Facilities
AAALAC-accredited and intelligent animal facilities
High-precision bioanalytical and identification instruments
-
Integrated Service
Screening to IND filing, In vitro and in vivo
Routine small molecules and new modalities
High-efficiency cross-department cooperation within the company
Stay Connected
Keep up with the latest news and insights.
